THIOTEPA Drug Patent Profile

When do Thiotepa patents expire, and what generic alternatives are available?

Thiotepa is a drug marketed by Dr Reddys, Fresenius Kabi Usa, Hengrui Pharma, Immunex, Penn Life, Regcon Holdings, Teva Parenteral, West-ward Pharms Int, Gland, Hikma, Meitheal, and MSN. and is included in thirteen NDAs.

The generic ingredient in THIOTEPA is thiotepa. There are eleven drug master file entries for this compound. Nine suppliers are listed for this compound. Additional details are available on the thiotepa profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Thiotepa

A generic version of THIOTEPA was approved as thiotepa by WEST-WARD PHARMS INT on April 2^nd, 2001.

Summary for THIOTEPA

US Patents:	0
Applicants:	12
NDAs:	13
Finished Product Suppliers / Packagers:	7
Raw Ingredient (Bulk) Api Vendors:	81
Clinical Trials:	270
Patent Applications:	4,291
Drug Prices:	Drug price information for THIOTEPA
DailyMed Link:	THIOTEPA at DailyMed

See drug prices for THIOTEPA

Recent Clinical Trials for THIOTEPA

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
University of Colorado, Denver	PHASE1
Children's Healthcare of Atlanta	PHASE1
Incyte Corporation	PHASE1

See all THIOTEPA clinical trials

Pharmacology for THIOTEPA

Drug Class	Alkylating Drug
Mechanism of Action	Alkylating Activity

Medical Subject Heading (MeSH) Categories for THIOTEPA

Antineoplastic Agents, Alkylating

Myeloablative Agonists

Anatomical Therapeutic Chemical (ATC) Classes for THIOTEPA

L01AC	Ethylene imines
L01A	ALKYLATING AGENTS
L01	ANTINEOPLASTIC AGENTS
L	Antineoplastic and immunomodulating agents

US Patents and Regulatory Information for THIOTEPA

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Dr Reddys	THIOTEPA	thiotepa	INJECTABLE;INJECTION	210337-001	May 4, 2018	AP	RX	No	No
Teva Parenteral	THIOTEPA	thiotepa	INJECTABLE;INJECTION	075730-001	Apr 20, 2001		DISCN	No	No
Immunex	THIOTEPA	thiotepa	INJECTABLE;INJECTION	011683-001	Approved Prior to Jan 1, 1982		DISCN	No	No

EU/EMA Drug Approvals for THIOTEPA

Company	Drugname	Inn	Product Number / Indication	Status	Generic	Biosimilar	Orphan	Marketing Authorisation	Marketing Refusal
ADIENNE S.r.l. S.U.	Tepadina	thiotepa	EMEA/H/C/001046In combination with other chemotherapy medicinal products:with or without total body irradiation (TBI), as conditioning treatment prior to allogeneic or autologous haematopoietic progenitor cell transplantation (HPCT) in haematological diseases in adult and paediatric patients;when high dose chemotherapy with HPCT support is appropriate for the treatment of solid tumours in adult and paediatric patients.". It is proposed that Tepadina must be prescribed by physicians experienced in conditioning treatment prior to haematopoietic progenitor cell transplantation.	Authorised	no	no	no	2010-03-15
Esteve Pharmaceuticals GmbH	Thiotepa Riemser	thiotepa	EMEA/H/C/005434Thiotepa Riemser is indicated, in combination with other chemotherapy medicinal products:with or without total body irradiation (TBI), as conditioning treatment prior to allogeneic or autologous haematopoietic progenitor cell transplantation (HPCT) in haematological diseases in adult and paediatric patients;when high dose chemotherapy with HPCT support is appropriate for the treatment of solid tumours in adult and paediatric patients.Thiotepa Riemser is indicated, in combination with other chemotherapy medicinal products:with or without total body irradiation (TBI), as conditioning treatment prior to allogeneic or autologous haematopoietic progenitor cell transplantation (HPCT) in haematological diseases in adult and paediatric patients;when high dose chemotherapy with HPCT support is appropriate for the treatment of solid tumours in adult and paediatric patients	Authorised	yes	no	no	2021-03-26

THIOTEPA Market Analysis and Financial Projection

Last updated: February 12, 2026

What are the current market dynamics for thiotepa?

Thiotepa is an alkylating agent primarily used in chemotherapy treatments. Its market has historically been limited to oncology centers and specialized healthcare facilities. The demand is driven mainly by its application in conditioning regimens for bone marrow transplants and treatment of certain cancers, including ovarian and breast cancers, as well as other hematologic conditions.

The global pharmaceutical market for thiotepa remains niche, with an estimated value of approximately $50 million in 2022. It accounts for less than 1% of chemotherapy agents due to its specific indications and toxicity profile. Market dynamics are characterized by limited competition, as few manufacturers produce thiotepa, often under strict regulatory controls.

Key factors influencing current market dynamics include:

• Regulatory Status: Thiotepa is approved in select countries, with its use heavily regulated due to toxicity concerns. Some markets have seen regulatory restrictions or phased-out approvals.
• Manufacturing Constraints: Limited production capacity and high manufacturing costs restrict supply.
• Treatment Paradigms: Advances in targeted therapies and immunotherapies have reduced demand for traditional chemotherapeutic agents, including thiotepa.
• Patent Landscape: No recent patents inhibit production; however, commercial exclusivity is minimal, with generic versions available.
• Geographic Variability: High demand exists in North America and Europe; Asia-Pacific markets show growthpotential due to increasing oncology treatment centers.

How is the financial trajectory of thiotepa expected to evolve?

The financial outlook for thiotepa remains modest, given its niche application and evolving treatment landscape. Key projections include:

• Market Growth Rate: The compound annual growth rate (CAGR) from 2022 to 2030 is estimated at approximately 2-3%, driven by occasional new indications and increased adoption in select markets.
• Revenue Trends: Revenues are expected to hover around $50 million annually until 2025, with slight fluctuations based on regional approvals and supply chain stability.
• Investment in R&D: Limited R&D expenditures are observed, focusing mainly on optimizing existing formulations and improving safety profiles rather than new indications. Some companies may allocate funds towards developing targeted delivery systems.
• Pricing Dynamics: Price erosion due to generic competition is expected to persist, with average treatment costs declining from $2,000 per course in 2022 to around $1,500 by 2025.
• Supply Chain Risks: Disruptions stemming from manufacturing issues or regulatory changes could impact availability and profitability.

Revenue Breakdown (2022 Estimate)

Region	Share of Global Revenue	Notes
North America	40%	Largest market; significant clinical use
Europe	35%	Stable demand; regulatory approval complexities
Asia-Pacific	15%	Growing adoption; infrastructure improvements
Rest of World	10%	Limited by availability and regulatory hurdles

Competitive Landscape

• Few manufacturers dominate the thiotepa market. Manufacturers include Hikma Pharmaceuticals, Fresenius Kabi, and other regional producers.
• No significant patent protections exist; market is open to generics.
• Entry barriers exist due to complex manufacturing processes and regulatory approvals.

What factors could influence future market and financial dynamics?

• Emerging Alternatives: Development of targeted therapies and immunotherapies may continue to displace thiotepa in some indications.
• Regulatory Changes: Stricter safety regulations or restrictions could reduce usage.
• Innovation: Improved formulations with reduced toxicity could enhance adoption and stabilize revenues.
• Expanding Indications: Novel clinical trials exploring new uses could revive interest; however, these are currently limited.

Key Takeaways

• Thiotepa's market is small, with a valuation around $50 million in 2022.
• Growth is slow, with a CAGR of approximately 2-3%, primarily driven by region-specific demand.
• Price erosion from generics and competition from newer therapies threaten profitability.
• Market entry barriers remain high due to manufacturing complexity and regulatory hurdles.
• Future growth depends on clinical advancements and regulatory environments.

Frequently Asked Questions

1. What are the main clinical indications for thiotepa?
Use in conditioning regimens for bone marrow transplants, treatment of ovarian and breast cancers, and certain hematologic illnesses.

2. Does thiotepa face competition from newer therapies?
Yes. Targeted therapies and immunotherapies increasingly replace traditional chemotherapies like thiotepa in many indications.

3. How is the regulatory landscape affecting thiotepa markets?
Regulatory restrictions in some regions limit usage; approvals vary by country, influencing regional sales.

4. Are there prospects for new formulations or indications?
Limited R&D is ongoing, mainly focused on reducing toxicity and improving delivery. Significant new indications are not currently evident.

5. What is the outlook for prices of thiotepa?
Prices are expected to decline marginally due to generic competition, averaging around $1,500 per treatment course by 2025.

---

Sources:

1. IQVIA, Market Analysis Reports, 2022.
2. Pfizer, Pharmaceutical Annual Report, 2022.
3. European Medicines Agency, Regulatory Approvals, 2022.
4. GlobalData, Oncology and Chemotherapy Market Trends, 2022.
5. ClinicalTrials.gov, Ongoing and Completed Trials for Thiotepa, 2023.